Medical technology company Chordate Medical has developed a CE-marked nerve stimulation treatment method that offers a drug-free alternative for chronic migraine. This treatment was previously called Kinetic Oscillation Stimulation (KOS), but now goes under the brand Ozilia Migraine.
Training in Liverpool supports market introduction
Ozilia is currently being introduced in the UK, Finland, and Germany, among others. As a step in the launch, Chordate Medical recently visited The Walton Centre, a leading neurological hospital with a catchment area of approximately four million people.
During September 6th – 7th, The Walton Center NHS Foundation Trust a neurology symposium in Liverpool, where Chordate Medical provided practical training in its treatment method to seven specialist doctors and nurses. The training was led by the company's clinical applications specialist Petra Libert.
Opportunities for Chordate Medical
With a staff of approximately 1 people, The Walton Centre treats over 450 patients annually in neurology, neurosurgery, pain management and rehabilitation. This makes the hospital a central hub for neurological healthcare in the region. Now the medical profession, primarily in private care, intends to introduce Ozilia into their treatment arsenal.
BioStock took the opportunity to ask Chordate Medical's CEO a few questions. Anders Weilandt to find out more about what this means for the company's marketing efforts.
First of all, how did the training go?
– The Ozilia treatment is easy to perform and learn, so the focus was first on assessing whether the patient's nose is suitable for the treatment and what to be vigilant about before prescribing the treatment. This was followed by a practical exercise in simply carrying out the treatment. Finally, of course, time for questions and discussion.
What's next now that the staff have been trained – when can we expect a commercial order from The Walton Centre?
– The clinic, which has already received equipment and materials for testing, now plans to initially treat 10 patients and evaluate the practical results. After that, we hope to move on to regular treatment of those patients who are suitable and who want to switch from drug treatment, or who are suitable for other reasons.
What other initiatives are you making to strengthen your market launches?
– Right now, the focus is fully on supporting customers who want to get started with practical use in our selected markets. This is happening everywhere where we have a presence. Of course, in the beginning it is a question of a few clinics in each market. But this is generally how it starts, first with one step and then one step at a time.
– As we have communicated, we are starting on the private clinic side with a few exceptions. The reason for this is obvious because there we find shorter decision-making paths, and the question of how and who should pay is much easier to handle.